This Article Full Text Full Text (PDF) Supplementary Data Correction (v67,p427) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Machida, E. O. Articles by Baylin, S. B. Search for Related Content PubMed PubMed Citation Articles by Machida, E. O. Articles by Baylin, S. B.

Hypermethylation of ASC/TMS1 Is a Sputum Marker for Late-Stage Lung Cancer

¹ The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; Departments of ² Surgery, ³ Pathology, and ⁴ Molecular Oncology, Shinshu University School of Medicine, Matsumoto, Nagano, Japan; and ⁵ Lovelace Respiratory Research Institute, Albuquerque, New Mexico

Requests for reprints: Stephen B. Baylin, Cancer Biology Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231. Phone: 410-955-8506; Fax: 410-614-9884; E-mail: sbaylin{at}jhmi.edu or Shun'ichiro Taniguchi, Department of Molecular Oncology, Shinshu University Graduate School of Medicine, Asahi 3-1-1, Matsumoto, Nagano 390-8621, Japan. Phone: 81-263-37-2724; Fax: 81-263-37-2724; E-mail; stangch{at}sch.md.shinshu-u.ac.jp.

DNA hypermethylated gene promoter sequences are extremely promising cancer markers. Their use for risk assessment, early diagnosis, or prognosis depends on the timing of this gene change during tumor progression. We studied this for the proapoptotic gene ASC/TMS1 in lung cancer and used the findings to develop a sputum marker. ASC/TMS1 protein levels are reduced in all lung cancer types (30 of 40; 75%) but not in 10 preinvasive lesions. Hypermethylation of ASC/TMS1 is also associated with invasive cancers (41 of 152 or 27.0% of all lung cancer types) with variation in incidence between histopathologic types including 32.1% (26 of 81) of adenocarcinomas, 13.2% (7 of 53) of squamous cell carcinomas, 38.5% (5 of 13) of large-cell carcinomas, and 60% (3 of 5) of small-cell lung cancers. The hypermethylation is particularly correlated with late tumor stages being present in only 14% of stage I but 60% of later-stage tumors. The incidence of ASC/TMS1 hypermethylation in sputum DNA fully mimics the tissue findings being present in only 2% (2 of 85) of high-risk, cancer-free smokers, 15% (3 of 18) of patients with stage I non–small-cell lung cancer (NSCLC), but 41% of patients with stage III NSCLC (18 of 44), including 56% (10 of 18) of those with adenocarcinoma. Importantly, sputum is positive for this marker in 24% (10 of 42) of very high risk, clinically cancer-free individuals previously resected for stage I NSCLC. Thus, hypermethylation of ASC/TMS1 is a marker for late-stage lung cancer and, in sputum, could predict prognosis in patients resected for early-stage disease. (Cancer Res 2006; 66(12): 6210-8)

This article has been cited by other articles:

				V. J. Bailey, H. Easwaran, Y. Zhang, E. Griffiths, S. A. Belinsky, J. G. Herman, S. B. Baylin, H. E. Carraway, and T.-H. Wang MS-qFRET: A quantum dot-based method for analysis of DNA methylation Genome Res., August 1, 2009; 19(8): 1455 - 1461. [Abstract] [Full Text] [PDF]

				R. S. Herbst, J. V. Heymach, and S. M. Lippman Lung Cancer N. Engl. J. Med., September 25, 2008; 359(13): 1367 - 1380. [Full Text] [PDF]

				J. D.F. Licchesi, W. H. Westra, C. M. Hooker, and J. G. Herman Promoter Hypermethylation of Hallmark Cancer Genes in Atypical Adenomatous Hyperplasia of the Lung Clin. Cancer Res., May 1, 2008; 14(9): 2570 - 2578. [Abstract] [Full Text] [PDF]

				M. V. Brock, C. M. Hooker, E. Ota-Machida, Y. Han, M. Guo, S. Ames, S. Glockner, S. Piantadosi, E. Gabrielson, G. Pridham, et al. DNA Methylation Markers and Early Recurrence in Stage I Lung Cancer N. Engl. J. Med., March 13, 2008; 358(11): 1118 - 1128. [Abstract] [Full Text] [PDF]

				S. Luxen, S. A. Belinsky, and U. G. Knaus Silencing of DUOX NADPH Oxidases by Promoter Hypermethylation in Lung Cancer Cancer Res., February 15, 2008; 68(4): 1037 - 1045. [Abstract] [Full Text] [PDF]

				S. Dubey and C. A. Powell Update in Lung Cancer 2006 Am. J. Respir. Crit. Care Med., May 1, 2007; 175(9): 868 - 874. [Full Text] [PDF]

				Correction: Hypermethylation of ASC/TMS1 in Lung Cancer Cancer Res., January 1, 2007; 67(1): 427 - 427. [Full Text] [PDF]